Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
SOTROVIMAB (SOE troe vi mab) is a monoclonal antibody. It is used to treat COVID-19 in patients who are not hospitalized. It is for patients at risk of getting severe symptoms of COVID-19. It may decrease the risk of developing severe symptoms of COVID-19. It may also decrease the chance of going to the hospital. This medicine is not approved by the FDA. The FDA has authorized emergency use of this medicine during the COVID-19 pandemic.
This medicine is injected into a vein. It is given by a health care provider in a hospital or clinic setting.
Talk to your health care provider about the use of this medicine in children. While it may be prescribed for children as young as 12 years of age for selected conditions, precautions do apply.
Side effects that you should report to your doctor or health care professional as soon as possible:
Side effects that usually do not require medical attention (report these to your doctor or health care professional if they continue or are bothersome):
This drug is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
This does not apply. This medicine is not for regular use.
Your condition will be monitored carefully while you are receiving this medicine. Visit your health care provider for regular checks on your progress. Tell your health care provider if your symptoms do not start to get better or if they get worse.
After receiving this medicine, wait at least 90 days before getting the COVID-19 vaccine. If you have already received your first dose of the COVID-19 vaccine, wait at least 90 days after getting this medicine before getting your second dose of vaccine.
Cookies are used by this site. To decline or learn more, visit our cookies page.